Lakewood-Amedex Biotherapeutics (Direct Listing)(LABT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LABT Lakewood-Amedex Biotherapeutics (Direct Listing)

盘后交易 11-06 17:26:08 EST

0.3863

-0.1543

-28.54%

盘后0.4094

+0.0231+5.98%

17:26 EST

最高0.4874	最低0.3336	成交量3,491万
今开0.4441	昨收0.5406	日振幅28.45%
总市值91.54万	流通市值32.75万	总股本236.97万
成交额1,517万	换手率4,118.52%	流通股本84.77万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":0.3863,"timestamp":1793998800000,"preClose":0.5406,"halted":0,"volume":34912706,"hourTrading":{"tag":"盘后","latestPrice":0.4094,"preClose":0.3863,"latestTime":"17:26 EST","volume":2588847,"amount":1091639.47692858,"timestamp":1794003968499,"change":0.0231,"changeRate":0.059798,"amplitude":0.232462},"delay":0,"changeRate":-0.2854236034036256,"floatShares":847700,"shares":2369700,"eps":-3.1005669,"marketStatus":"盘后交易","change":-0.1543,"latestTime":"11-06 17:26:08 EST","open":0.44405,"high":0.4874,"low":0.3336,"amount":15173312.70082908,"amplitude":0.284499,"askPrice":0.42,"askSize":1000,"bidPrice":0.4042,"bidSize":620,"shortable":0,"etf":0,"ttmEps":-3.1005669,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1794013200000},"marketStatusCode":4,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":0.5406,"preHourTrading":{"tag":"盘前","latestPrice":0.4468,"preClose":0.5406,"latestTime":"09:29 EST","volume":8986763,"amount":4309064.7882226,"timestamp":1793975399313,"change":-0.0938,"changeRate":-0.173511,"amplitude":0.27266},"postHourTrading":{"tag":"盘后","latestPrice":0.4094,"preClose":0.3863,"latestTime":"17:26 EST","volume":2588847,"amount":1091639.47692858,"timestamp":1794003968499,"change":0.0231,"changeRate":0.059798,"amplitude":0.232462},"volumeRatio":0.230071},"requestUrl":"/m/hq/s/LABT/tweets","defaultTab":"tweets","newsList":[{"id":"1176530600","title":"Lakewood-Amedex Biotherapeutics提交招股说明书，特定售股股东拟转售至多451.24万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1176530600","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176530600?lang=zh_cn&edition=full","pubTime":"2026-09-19 05:33","pubTimestamp":1789767200,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics向美国证券交易委员会（SEC）提交了招股说明书文件，该文件涉及特定售股股东对至多4,512,400股普通股的转售安排。\n根据这份SEC备案文件，公司将针对上述数量的普通股进行转售登记。这一举措旨在为符合条件的售股股东提供股份流通的通道，但公司本身并未通过此次转售获得任何资金收益。\n本次转售计划的核心在于，相关售股股东将依照市场条件和监管框架，在适当时机灵活执行股份出售操作，以优化其投资组合结构或实现资产配置目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104076244","title":"Lakewood-Amedex Biotherapeutics宣布IRB批准及临床试验点就绪，即将启动Nu-3治疗感染性糖尿病足溃疡的2a期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1104076244","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104076244?lang=zh_cn&edition=full","pubTime":"2026-09-18 20:15","pubTimestamp":1789733713,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics今日宣布，其机构审查委员会批准已获通过，同时临床试验站点也已完成准备工作，这标志着该公司针对感染性糖尿病足溃疡治疗药物Nu-3的2a期临床试验即将正式启动。Nu-3正是针对这一临床需求而研发的新型治疗候选药物。公司在声明中表示，IRB的批准和临床基地的同步就绪，为试验的顺利展开铺平了道路。2a期临床试验的启动，不仅体现了Lakewood-Amedex在抗感染和伤口愈合领域的持续深耕，也为患者群体带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105205621","title":"Lakewood-Amedex Biotherapeutics 完成感染性糖尿病足溃疡二期a阶段试验最终筹备","url":"https://stock-news.laohu8.com/highlight/detail?id=1105205621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105205621?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:04","pubTimestamp":1784117062,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 已进入其针对感染性糖尿病足溃疡治疗的二期a阶段临床试验的最终准备阶段。公司正集中资源推进试验流程，标志着其核心疗法开发进入关键节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146064134","title":"Lakewood-Amedex Biotherapeutics - Nu-3在临床前研究中展现良好耐受性，高剂量下系统暴露量低","url":"https://stock-news.laohu8.com/highlight/detail?id=1146064134","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146064134?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:03","pubTimestamp":1784117015,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics（直接上市）宣布，其候选药物Nu-3在近期完成的临床前研究中取得了积极结果。数据显示，即使在较高剂量下，Nu-3也表现出良好的耐受性，且系统暴露水平维持在较低范围。这一发现为该药物的进一步开发提供了重要的安全性依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125245294","title":"Lakewood-Amedex Biotherapeutics公布临床前安全性数据，支持Nu-3凝胶即将开展的2a期试验剂量选择","url":"https://stock-news.laohu8.com/highlight/detail?id=1125245294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125245294?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:03","pubTimestamp":1784116990,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics公司宣布了其Nu-3凝胶的临床前安全性数据。这些关键数据为即将启动的2a期临床试验中的临床剂量选择提供了有力支持。研究结果表明，Nu-3凝胶在所测试的剂量范围内展现出良好的安全性特征，这为后续临床研究的顺利推进奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150730441","title":"Lakewood-Amedex Biotherapeutics 准备推进 Nu-3 针对感染性糖尿病足溃疡的二期临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1150730441","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150730441?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:08","pubTimestamp":1783426135,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 正准备将其候选药物 Nu-3 推进至二期临床开发阶段，该药物旨在治疗感染性糖尿病足溃疡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155453862","title":"Lakewood-Amedex Biotherapeutics 宣布普通股1比10反向拆股 - 美国证券交易委员会文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1155453862","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155453862?lang=zh_cn&edition=full","pubTime":"2026-06-17 23:42","pubTimestamp":1781710936,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 已向美国证券交易委员会提交文件，宣布对其已发行的普通股进行一比十的反向股票分割。\n此项公司行动旨在调整其股本结构。反向拆股预计将于近期生效，具体细节请参阅公司提交的正式监管文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187732926","title":"Lakewood-Amedex Biotherapeutics：关键制剂、递送与生产步骤完成，为计划中的二期临床试验做准备","url":"https://stock-news.laohu8.com/highlight/detail?id=1187732926","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187732926?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:06","pubTimestamp":1779105973,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 宣布，已成功完成关键制剂、药物递送及生产工艺步骤，为其计划开展的二期临床试验做好了充分准备。这些进展标志着公司在推进其候选疗法方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165537088","title":"Lakewood-Amedex Biotherapeutics 宣布其领先候选药物 Nu-3 在治疗感染性糖尿病足溃疡方面取得积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1165537088","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165537088?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:03","pubTimestamp":1779105797,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 公布了其领先候选药物 Nu-3 在治疗感染性糖尿病足溃疡方面取得积极数据，这标志着该药物研发进程的又一重要进展。这些数据为 Nu-3 的进一步临床开发提供了有力支持，有望为这一难治性感染领域带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184734412","title":"Lakewood-Amedex Biotherapeutics 宣布与Peri达成协议，后者将担任Nu-3二期临床试验的合同研究组织","url":"https://stock-news.laohu8.com/highlight/detail?id=1184734412","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184734412?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:03","pubTimestamp":1778587406,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 已正式宣布与Peri公司达成一项合作协议。根据协议条款，Peri公司将作为合同研究组织，负责其候选药物Nu-3的二期临床试验工作。此举标志着该药物研发进程迈入了新的关键阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://lakewoodamedex.com","stockEarnings":[{"period":"1week","weight":1.2781},{"period":"1month","weight":-0.3765},{"period":"3month","weight":-0.7565},{"period":"6month","weight":-0.9826},{"period":"1year","weight":-0.9932},{"period":"ytd","weight":-0.9932}],"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.0521},{"period":"6month","weight":-0.0063},{"period":"1year","weight":0.0818},{"period":"ytd","weight":0.0749}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Lakewood-Amedex Biotherapeutics Inc.最初于2006年7月11日在特拉华州注册成立。该公司是一家私营制药公司，专注于通过开发其双磷酸霉素来应对抗菌素耐药性（AMR）的全球健康危机类抗菌剂。该公司的方法涉及一种新机制，旨在迅速破坏细菌膜的稳定性，这可能会降低耐药性发展的可能性。他们的先导化合物Nu-3目前正处于治疗感染的糖尿病足溃疡的临床试验中，被配制为外用凝胶，可提供快速的抗菌作用和靶向递送。除了糖尿病足溃疡，该公司正在探索在治疗复杂的尿路感染和肺部感染方面的应用。","exchange":"NASDAQ","name":"Lakewood-Amedex Biotherapeutics (Direct Listing)","nameEN":"Lakewood-Amedex Biotherapeutics (Direct Listing)"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lakewood-Amedex Biotherapeutics (Direct Listing)(LABT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Lakewood-Amedex Biotherapeutics (Direct Listing)(LABT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Lakewood-Amedex Biotherapeutics (Direct Listing),LABT,Lakewood-Amedex Biotherapeutics (Direct Listing)股票,Lakewood-Amedex Biotherapeutics (Direct Listing)股票老虎,Lakewood-Amedex Biotherapeutics (Direct Listing)股票老虎国际,Lakewood-Amedex Biotherapeutics (Direct Listing)行情,Lakewood-Amedex Biotherapeutics (Direct Listing)股票行情,Lakewood-Amedex Biotherapeutics (Direct Listing)股价,Lakewood-Amedex Biotherapeutics (Direct Listing)股市,Lakewood-Amedex Biotherapeutics (Direct Listing)股票价格,Lakewood-Amedex Biotherapeutics (Direct Listing)股票交易,Lakewood-Amedex Biotherapeutics (Direct Listing)股票购买,Lakewood-Amedex Biotherapeutics (Direct Listing)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lakewood-Amedex Biotherapeutics (Direct Listing)(LABT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Lakewood-Amedex Biotherapeutics (Direct Listing)(LABT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}